[1]刘玉霞,胡国瑜,袁朝晖,等.CD269和CD317在多发性骨髓瘤中的表达及临床意义[J].现代检验医学杂志,2018,33(02):58-61.[doi:10.3969/j.issn.1671-7414.2018.02.001]
　LIU Yu-xia,HU Guo-yu,YUAN Chao-hui,et al.Expression of CD269 and CD317 in Multiple Myeloma and Its Clinical Significance[J].Journal of Modern Laboratory Medicine,2018,33(02):58-61.[doi:10.3969/j.issn.1671-7414.2018.02.001]
点击复制

CD269和CD317在多发性骨髓瘤中的表达及临床意义()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第33卷
期数:
2018年02期
页码:
58-61
栏目:
论著
出版日期:
2018-04-05

文章信息/Info

Title:
Expression of CD269 and CD317 in Multiple Myeloma and Its Clinical Significance
文章编号:
1671-7414(2018)02-058-04
作者:
刘玉霞; 胡国瑜; 袁朝晖; 谭 奎; 李清照; 沈婵娟
株洲市中心医院血液科,湖南株洲 412007
Author(s):
LIU Yu-xia; HU Guo-yu; YUAN Chao-hui; TAN Kui; LI Qing-zhao; SHEN Chan-juan
Department of Hematology, Zhuzhou Central Hospital,Hunan Zhuzhou 412000,China
关键词:
多发性骨髓瘤;  CD269;  CD317;  流式细胞术
分类号:
R733.3; R730.43
DOI:
10.3969/j.issn.1671-7414.2018.02.001
文献标志码:
A
摘要:
目的 通过研究多发性骨髓瘤(multiple myeloma,MM)患者骨髓细胞中CD269和CD317的抗原表达情况,分析其与反映MM疾病进展实验室指标的相关性,并评估其在临床诊疗中的价值。方法 采用病例对照性研究,选取63例初诊MM患者作为研究组,35例缺铁性贫血(IDA)患者作为对照组,应用流式细胞术检测两组患者骨髓血中CD269和CD317表达率以及63例MM患者骨髓血中其他抗原(CD19,CD20,CD56,CD117)的表达率; 分别检测MM患者血清血红蛋白(Hb)、血清β2微球蛋白(β2-MG)和乳酸脱氢酶(LDH)的浓度; 统计学分析CD269和CD317的表达水平并比较与其他实验室相关指标检测水平的相关性。结果 研究组和对照组的CD269阳性率分别为(86.6±2.35)%vs(4.33±1.69)%,差异具有统计学意义(t=4.256,P<0.05); CD317阳性率分别为(71.42±0.62)% vs(8.32±3.89)%,差异具有统计学意义(t=3.102,P<0.05); 在其他抗原表达上,CD269和CD317阳性组CD56的表达水平显著高于阴性组(t=4.032,P<0.05),而CD117的表达水平阳性组显著低于阴性组(t=2.832,P<0.05),CD19,CD20的表达两组间差异无统计学意义(P>0.05); MM患者CD269和CD317表达水平与CD56表达水平呈正相关(r=0.392,P<0.05),与CD117表达水平呈负相关(r=-0.210,P<0.05)。Hb含量阳性组明显低于阴性组(t=3.012,P<0.05),血清β2-MG 水平阳性组低于阴性组(t=2.024,P<0.05),血清LDH水平两组间差异无统计学意义(P>0.05); MM患者CD269和CD317表达水平与血清Hb含量呈负相关(r=-0.212,P<0.05),与血清β2-MG水平呈负相关(r=-0.312,P<0.05)。结论 MM患者骨髓细胞高表达CD269和CD317; MM的病情进展与患者CD56升高或CD117降低有关; 与血清Hb含量和β2-MG水平降低有关,有助于判断病情严重程度及评估预后。
Abstract:
Abstract:Objective To study the expression of CD269 andCD317 antigens in bone marrow cells of patients with multiple myeloma(MM),analyze its correlation with the laboratory indexes reflecting the progression of MMand evaluate its value in clinical diagnosis and treatment.Methods63 newly diagnosed MM patients were selected as the study group by a case-control study.The expression rate of CD269 and CD317 in bone marrow blood of 35 patients with iron deficiency anemia and other antigens in bonemarrow blood of 63 patients with MM were detected by flow cytometry.The levelsof serum hemoglobin(Hb),serum β 2 -MG(β2 - MG)and lactate dehydrogenase(LDH)in patients with MM were detected,and the levels of CD269 and CD317were analyzed statistically.Results The positive rates of CD269 in the study group and control group were(86.6±2.35)% vs(4.33±1.69)%,respectively(t=4.256,P<0.05)).The positive rate of CD317 was(71.42+0.62)% vs(8.32+3.89)%,the difference was statistically significant(t=3.102,P<0.05).In other expression,the expression level of CD269 and CD317 in CD56 positive group was significantly higher than that of negative group(t=4.032,P<0.05),while the expression of CD117 the level of positivegroup was significantly lower than that of the negative group(t=2.832,P<0.05),CD19,CD20 expression was not statistically significant difference between the two groups(P>0.05).The levels of CD269 and CD317 in patients withMM were positively correlated with the level of CD56 expression(r=0.392,P<0.05),and negatively correlated with the level of CD117 expression(r=-0.210,P<0.05).The levels of CD269 and CD317 in patients with MM were significantly lower than those in the negative group(t=3.012,P<0.05)and the levels of serum LDH in the positive group were lower than those inthe negative group(t=2.024,P<0.05).There was a negative correlation between Hb content(r=-0.212,P<0.05)and negatively correlated with serum β2-MG(r=-0.312,P<0.05).Conclusion The high expression of CD269 and CD317 in bone marrow cells in MM patients is related to the increase of CD56 and decrease of CD117 in patients with MM.

参考文献/References:

[1] Blimark C,Holmberg E,Mellqvist UH,et al.Multiple myeloma andinfections:a population-based study on 9 253 multiple myeloma patients[J].Haematology,2015,100(1):107-113.
[2] Pratt G,Goodyear O,Moss P,et al.Immunodeficiency and immunotherapy inmultiple myeloma[J].Br J Haematology,2007,138(5):563-579.
[3] Tai YT,Acharya C,An G,et al.APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment[J].Blood,2016,127(25):3225-3236.
[4] Oden F,Marino SF,Brand J,et al.Potent anti-tumor response by targeting B cell maturation antigen(BCMA)in a mouse model of multiple myeloma[J].Mol Oncol,2015,9(7):1348-1358.
[5] Ohtomo T,Sugamata Y,Ozaki Y,et al.Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells[J].Biochemical and Biophysical Research Communications,1999,258(3):583-591.
[6] Hobbs CA,Sherman SL,Yi P,et al.Polymorphisms in genes involved in folate metabolism as maternal risk factors for Down syndrome[J].Am J Hum Genet,2000,67(3):623-630.
[7] Lied GA,Berstad A.Functional and clinical aspects of the B-cell-activating factor(BAFF): a narrative review[J].Scand J Immunol,2011,73(1):1-7.
[8] Lemancewicz D,Bolkun L,Jablonska E,et al.Evaluation of TNF superfamily molecules in multiple myeloma patients:correlation with biological and clinical features[J].Leuk Res,2013,37(9):1089-1093.
[9] Swiecki M,Omattage NS,Brett TJ.BST-2/tetherin:structural biology,viral antagonism,and immunobiology of a potent host antiviral factor[J].Molecular Immunology,2013,54(2):132-139.
[10] Sayeed A,Luciani-Torres G,Meng Z,et al.Aberrant regulationof the BST2(Tetherin)promoter enhances cell proliferation and apoptosis evasion in high grade breast cancer cells[J].PLoS One,2013,8(6):440-441.
[11] Fang KH,Kao HK,Chi LM,et al.Overexpression of BST2 is associated with nodal metastasis and poorer prognosis in oral cavity cancer[J].the Laryngoscope,2014,124(9):E354-E360.
[12] Gong S,Osei ES,Kaplan D,et al.CD317 is over-expressed in B-cell chronic lymphocytic leukemia,but not B-cell acute lymphoblastic leukemia [J].International Journal of Clinical & Experimental Pathology,2015,8(2):1613-1621.
[13] Chiriva-Inernati M,Liu Y,Weidanz JA,et al.Testing recombinantadeno-associated virus-gene loading of dendritic cells for generating potent cytotoxic T lymphocytes against a prototype self-antigen, multiple myeloma HM1.24[J].Blood,2003,102(9):3100-3107.
[14] Carpenter RO,Evbuomwan MO,Pittaluga S,et al.B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma[J].Clin Cancer Res,2013,19(8):2048-2060.
[15] Blaheta RA,Beecken WD,Engl T,et al.Human cytomegalovirus infection of tumor cells downregulates NCAM(CD56):a novel mechanism for virus-induced tumor invasiveness[J].Neoplasia,2004,6(4):323-331.
[16] Pan Y,Wang H,Tao Q,et al.Absence of both CD56 and CD117 expression on malignant plsma cells is related with a poor prognosis in patients with newlydiagnosed multiple myeloma[J].Leuk Res,2016,40(1):77-82.
[17] 段丽娟,李 超,杨如玉.多发性骨髓瘤患者血清β2-微球蛋白,TNF-α,CRP及IL-6水平检测[J].中国实验血液学杂志,2015,23(5):1362-1365. Duan LJ,Li C,Yang RY.Values of detecting the levels of β2-MG,TNF-α,CRP,IL-6 in the patients with multiple myeloma[J].Journalof Experimental Hematology,2015,23(5):1362-1365.
[18] Bataille R,Annweiler C,Beaucher O,et al.Multiple myeloma international staging system:“staging” or simply “aging” system[J].Clin Lymphoma Myeloma Leuk,2013,13(6):635-637.
[19] 秦小琪,徐 燕,安 刚,等.肾功能对β2-微球蛋白水平作为多发性骨髓瘤国际分期系统预后因素的影响-单中心666例临床分析[J].中华血液学杂志,2015,36(5):393-397. Qin XQ,Xu Y,An G,et al.The impact of renal function on prognostic value β2-microglobulin of ISS stage system in multiple myeloma patients:a clinical data analysis of 666 patients in a single center[J].Chin J Hematol,2015,36(5):393-397.
[20] 何亚利,梁顺容,范佳鑫.多发性骨髓瘤患者和厚朴酚联合三氧化二砷治疗前后血清β2-MG及LDH的变化[J].检验医学,2016,31(6):449-452. He YL,Liang SR,Fan JX,et al.Changes of serum β2-MG and LDH in combination theraphy of multiple myeloma with honokiol and arsenic trioxide[J].Laboratory Medicine,2016,31(6):449-452.

相似文献/References:

[1]韩秀蕊,杨娣娣,李艳春,等.多发性骨髓瘤患者骨髓涂片与骨髓活检同步检查的比较分析[J].现代检验医学杂志,2015,30(03):129.[doi:10.3969/j.issn.1671-7414.2015.03.039]
　HAN Xiu-rui,YANG Di-di,LI Yan-chun,et al.Comparative Analysis of Bone Marrow Smears and Biopsies Synchronous Check for Myeloma Patients[J].Journal of Modern Laboratory Medicine,2015,30(02):129.[doi:10.3969/j.issn.1671-7414.2015.03.039]
[2]邱 爽,孟瑞芳,蒋筱漪,等.血清免疫固定电泳、蛋白电泳、免疫球蛋白及轻链定量在诊断多发性骨髓瘤中的临床应用[J].现代检验医学杂志,2015,30(02):61.[doi:10.3969/j.issn.1671-7414.2015.02.019]
　QIU Shuang,MENG Rui-fang,JIANG Xiao-yi,et al.Clinical Application of Immunofixtion Electrophoresis, Serum Protein Electrophoresis and Immunoglobulins and Light Chain Quantitative Analysis in the Diagnosis of Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2015,30(02):61.[doi:10.3969/j.issn.1671-7414.2015.02.019]
[3]李 瑛,李 军.多发性骨髓瘤患者血清中IL-6与IL-27水平监测的临床应用[J].现代检验医学杂志,2016,31(04):87.[doi:10.3969/j.issn.16717-414.2016.04.023]
　LI Ying,LI Jun.Clinical Application of Monitoring IL-6 and IL-27 Levels in Patients with Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2016,31(02):87.[doi:10.3969/j.issn.16717-414.2016.04.023]
[4]郭进京,胡林辉,陶千山,等.红细胞分布宽度在多发性骨髓瘤患者预后分期中的价值[J].现代检验医学杂志,2017,32(03):34.[doi:10.3969/j.issn.1671-7414.2017.03.009]
　GUO Jin-jing,HU Lin-hui,TAO Qian-shan,et al.Value of Red Cell Distribution Width in the Prognosis of Patients with Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2017,32(02):34.[doi:10.3969/j.issn.1671-7414.2017.03.009]
[5]盘国雄,谭才燕,何嘉颖,等.多发性骨髓瘤患者血清中lncRNA PCAT-1的表达水平与临床预后研究[J].现代检验医学杂志,2018,33(01):72.[doi:10.3969/j.issn.1671-7414.2018.01.001]
　PAN Guo-xiong,TAN Cai-yan,HE Jia-ying,et al.Serum LncRNA PCAT-1 Expression Level of Patients with Multiple Myeloma and Clinical Value[J].Journal of Modern Laboratory Medicine,2018,33(02):72.[doi:10.3969/j.issn.1671-7414.2018.01.001]
[6]张 蓉,李国辉,刘小五,等.初诊多发性骨髓瘤患者外周血淋巴细胞绝对值/ 单核细胞绝对值比值在预测临床预后的价值研究[J].现代检验医学杂志,2020,35(01):101.[doi:10.3969/j.issn.1671-7414.2020.01.027]
　ZHANG Rong,LI Guo-hui,LIU Xiao-wu,et al.Value of Peripheral Blood Lymphocyte Absolute Value/Monocyte Absolute Value Ratio in Predicting Clinical Prognosis of Newly Diagnosed MultipleMyeloma Patients[J].Journal of Modern Laboratory Medicine,2020,35(02):101.[doi:10.3969/j.issn.1671-7414.2020.01.027]
[7]霍 豆,秦 爽,吴永昌,等.血清总轻链与游离轻链定量检测在多发性骨髓瘤诊断中的临床价值探讨[J].现代检验医学杂志,2020,35(04):87.[doi:10.3969/j.issn.1671-7414.2020.04.021]
　HUO Dou,QIN Shuang,WU Yong-chang,et al.Clinical Value of Quantitative Detection of sTLC and sFLC in Diagnosis of Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2020,35(02):87.[doi:10.3969/j.issn.1671-7414.2020.04.021]
[8]何　进,张　艳,申娴娟,等.多发性骨髓瘤患者血清可溶性PD-L1水平在辅助诊断及临床分型的价值研究[J].现代检验医学杂志,2021,36(02):15.[doi:doi:10.3969/j.issn.1671-7414.2021.02.004]
　HE Jin,ZHANG Yan,SHEN Xian-juan,et al.Value of Blood Soluble PD-L1 in the Auxiliary Diagnosis and Clinical Subtype of Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2021,36(02):15.[doi:doi:10.3969/j.issn.1671-7414.2021.02.004]
[9]徐海燕,陆学东.多发性骨髓瘤早期实验诊断相关新兴生物标志物的最新研究进展[J].现代检验医学杂志,2021,36(05):180.[doi:10.3969/j.issn.1671-7414.2021.05.039]
　XU Hai-yan,LU Xue-dong.Recent Research Rrogress of Novel Biomarkers for Early ExperimentalDiagnosis of Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2021,36(02):180.[doi:10.3969/j.issn.1671-7414.2021.05.039]
[10]侯艳军,张秋怡,单志娟,等.多发性骨髓瘤患者骨髓中CD56和CD117水平表达对评估疾病预后的价值[J].现代检验医学杂志,2021,36(06):74.[doi:10.3969/j.issn.1671-7414.2021.06.015]
　HOU Yan-jun,ZHANG Qiu-yi,SHAN Zhi-juan,et al.Significance of the Expression of CD56 and CD117 in Evaluating the Prognosis of Patients with Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2021,36(02):74.[doi:10.3969/j.issn.1671-7414.2021.06.015]
[11]谭 奎,沈婵娟,张 玲,等.多发性骨髓瘤患者骨髓CD269和CD317基因的差异性表达研究[J].现代检验医学杂志,2017,32(06):64.[doi:10.3969/j.issn.1671-7414.2017.06.001]
　TAN Kui,SHEN Chan-juan,ZHANG Ling,et al.Differential Expression of CD269 and CD317 Genes in Bone Marrow of Patients with Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2017,32(02):64.[doi:10.3969/j.issn.1671-7414.2017.06.001]

备注/Memo

备注/Memo:
基金项目:湖南省卫计委资助课题(c2015-075)。 作者简介:刘玉霞(1977-),女,硕士研究生,助理研究员,主要从事流式细胞术检测工作,E-mail:632410858@qq.com。 通讯作者:沈婵娟(1982-),女,副主任医师,研究方向:血液系统疾病,E-mail:shenchanjuan@163.com。
更新日期/Last Update: 2018-04-16